This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The study evaluated screening and surveillance colonoscopy, with the latter scheduled according to national German guidelines. This was compared with no screening.
Location/setting
Germany/secondary care.
Methods

Analytical approach:
A model was used to facilitate the synthesis of the costs and effectiveness data with much of the demographic and clinical data coming from a large scale online registry of screening colonoscopies. The time horizon of the study was 10 years. The authors stated that the study perspective was that of a third-party payer.
Effectiveness data:
The evidence came from a combination of data from the online registry and published studies. The authors did not report any search methods or inclusion criteria. The main clinical parameter was the number of cases of colorectal cancer prevented.
Monetary benefit and utility valuations:
None.
Measure of benefit:
The authors considered the measure of benefit to be the cost-savings. However, the cost-savings were based on the number of colorectal cancers avoided.
Cost data:
The costs included were for colonoscopy, adverse events, and diagnosis and treatment. Colonoscopy costs were based on payments of insurance companies according to the contract with the association of physicians. Cost for adverse events and for the diagnosis and treatment of colorectal cancer were obtained from published studies. All costs were reported in euros (EUR), although the price year was not reported. Discounting was performed and details were
